Dr. Mark McGovern

Dr. Mark McGovern is a Professor in the Department of Psychiatry & Behavioral Sciences and, by courtesy, the Department of Medicine at Stanford University School of Medicine. He is the Co-Chief of the Division of Public Mental Health and Population Sciences in the Department of Psychiatry, and Medical Director of Integrated Behavioral Health in the Division of Primary Care and Population Health in the Department of Medicine.

Dr. McGovern’s overarching goal is to improve access to the most effective care possible for anyone who needs it.

His primary research focus is implementation science, with a specific emphasis on integrated behavioral health services for persons with co-occurring substance use and psychiatric disorders, as they present in both primary care and specialty settings. Dr. McGovern has received a National Institute on Drug Abuse (NIDA) career development award and NIDA and National Institute on Alcohol Abuse and Alcoholism (NIAAA) grant funding to translate evidence-based therapies for complex patients into routine clinical settings. He has also received awards from the Robert Wood Johnson Foundation and the US Department of Health & Human Services’ Substance Abuse and Mental Health Services Administration (SAMHSA) to advance a series of organizational measures of integrated service capacity. These measures, the Dual Diagnosis Capability in Addiction Treatment (DDCAT), Dual Diagnosis Capability in Mental Health Treatment (DDCMHT) and Behavioral Health Integration in Medical Care (BHIMC), have been widely adopted and are being used to implement evidence-based treatments in community settings and systems throughout the United States and globally.

Presently, he leads national, State of California, and local efforts to combat the US opioid epidemic. Dr. McGovern’s work is focused on scaling up access to FDA-approved medications, in specialty care and in primary care and other general medical practice settings. His work is supported by NIDA, SAMHSA and the California Health Care Foundation. He is also actively collaborating with health systems, including Stanford Health Care and Intermountain Healthcare, on implementable and sustainable models of integrated behavioral health in primary care practice. This work is funded by the Department of Medicine, the Stanford-Intermountain Collaborative Grant Program, and the Patient Centered Outcomes Research Initiative (PCORI).

He is the PI on the National Coordinating Office of the Mental Health Technology Transfer Center (MHTTC) Network funded by SAMHSA. The MHTTC Network consists of 10 regional centers and 1 Native American/Tribal Center and 1 Latino/Hispanic Center–12 centers in all. The overarching goal of this network is the implementation and sustainment of evidence-based mental health prevention and treatment practices across US states and territories.

Dr. McGovern has been actively involved in the education of medical students, psychiatric residents and fellows, and clinical psychology interns at Stanford, and previously at the medical schools at Dartmouth (Lebanon, New Hampshire) and Northwestern University (Chicago, Illinois). From 2009 to 2017, he served as the Editor-In-Chief for the Journal of Substance Abuse Treatment (JSAT), the leading scientific journal dedicated to addiction treatment services and implementation research. Dr. McGovern is on the Core Faculty of the National Institute for Mental Health Implementation Research Institute and is a mentor to NIDA Fellows. He also serves on the NIDA Scientific Review Committee for Interventions for the Prevention and Treatment of Addiction.

IIBHN 2020 Presentation(s):

Integrating Medications for Addiction Treatment in Primary Care
Wednesday, April 1st, 2020. 10:15 – 12:00

Jr Ballroom 13022

Learning Objectives:

  • To apprehend the dynamic nature and scope of the US opioid epidemic and evidence-based responses.
  • To acquire practical knowledge of strategies to implement high-quality medications for addiction treatment into primary care practice for patients who are a) transitioning from chronic opioid therapy; and b) suffering from opioid use disorders.
Raoul RolfesDr. Mark McGovern